<p>Thiotepa Riemser is used in combination with chemotherapy in two ways:</p><ul><li>as a ‘conditioning’ (preparative) treatment before transplantation of haematopoietic progenitor cells (the cells that make blood cells). This type of transplant is used in patients who need replacement blood-making cells because they have a blood disease such as a cancer of the blood (e.g. leukaemia) or diseases causing low red-blood cell counts (including thalassaemia or sickle-cell anaemia);</li> <li>during the treatment of solid tumours when high-dose chemotherapy followed by transplantation of haematopoietic progenitor cells is needed.</li> </ul><p>Thiotepa Riemser can be used for transplantation of progenitor cells from a donor or for transplantation of progenitor cells from the patient’s own body.</p><p>Thiotepa Riemser contains the active substance thiotepa and is a ‘generic medicine’. This means that Thiotepa Riemser contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Tepadina. For more information on generic medicines, see the question-and-answer document below.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:</p> <ul><li>with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;</li> <li>when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.</li> </ul><p>Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:</p> <ul><li>with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;</li> <li>when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients</li> </ul></div>
Therapeutic Area (MeSH)
ATC Code
L01AC01
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| thiotepa | N/A | thiotepa |
EMA Name
Thiotepa Riemser
Medicine Name
Thiotepa Riemser
Aliases
N/ANo risk management plan link.
